Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

tenofovir disoproxil

TENOFOVIR ARX

tenofovir disoproxil (TENOFOVIR ARX) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

EMA: approved TGA: approved Antiinfectives for systemic use (J05) J05AF07
Patents linked 20
Pipeline programs 17
News articles 0
Drug details — tenofovir disoproxil
Class
Antiinfectives for systemic use (J05)
Route
—
Patents
20
Programs
17
Data quality
0.83
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

tenofovir disoproxil (TENOFOVIR ARX) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

Key facts

INN tenofovir disoproxil
Brand TENOFOVIR ARX
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AF07
Originator Alphapharm Pty Ltd

Approval history

Authority Status Date
EMA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. CVAY736F12301 Phase 3 · Novartis India · Systemic Lupus Erythematosus
  2. CVAY736F12302 Phase 3 · Novartis India · Systemic Lupus Erythematosus
  3. CVAY736K12301 Phase 3 · Novartis India · Lupus nephritis
  4. CVAY736K12301E1 Phase 3 · Novartis India · Lupus nephritis
  5. GS-US-174-0144 Phase 3 · Gilead Sciences · Hepatitis B Infection
  6. GS-US-528-6727 Phase 3 · Gilead Sciences · Human Immunodeficiency Virus (HIV-1) infection
  7. GS-US-563-5926 Phase 3 · Gilead Sciences · HIV-1 Infection
  8. MK-8527-011 Phase 3 · MSD Merck Sharp · HIV-1 prevention

Related & competitor drugs

Browse all drugs
  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Related patents

Browse patents Alphapharm Pty Ltd patent hub

  1. US 12384779

    Bicyclic compounds

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12180192

    Modulators of THR-β and methods of use thereof

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12018015

    Methods and compositions for targeting PD-L1

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957683

    Bicyclic compounds

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11952374

    Bicyclic compounds

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11939581

    Methods and compositions for targeting PD-L1

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11858913

    Bicyclic pyridazinones and methods of use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11840532

    Modulators of THR-β and methods of use thereof

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11820773

    Tricyclic compounds

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11793815

    Oxindoles and methods of use thereof

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11786532

    2-pyridones and methods of use thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11771680

    Pyrrole compounds

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11760764

    Methods and compositions for targeting PD-L1

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11760761

    Methods and compositions for targeting PD-L1

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11613750

    Methods of reducing virus molecule levels

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11591341

    Bicyclic and tricyclic compounds

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11464783

    Heterocyclic compounds

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11198699

    Compounds targeting PRMT5

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11191747

    Pyrrole compounds

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11136321

    Tricyclic compounds

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is tenofovir disoproxil?

tenofovir disoproxil (TENOFOVIR ARX) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

What is the brand name for tenofovir disoproxil?

TENOFOVIR ARX is a marketed brand name for tenofovir disoproxil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.